Pembrolizumab at Home vs Hospital: What Is the Difference?

For most of pembrolizumab's history, receiving it meant a trip to an oncology unit. A nurse would insert a cannula, connect an IV bag, and the infusion would run for around 30 minutes - followed by a period of observation before you could leave. That was the settled routine, until the subcutaneous formulation changed the picture entirely.

The traditional hospital route

IV pembrolizumab has been administered in hospital settings since its approval. For patients with good mobility and energy, a visit to the oncology day unit every three weeks may be manageable. But for many - particularly those living at a distance from specialist centres, or whose condition affects stamina - repeated hospital visits represent a significant ongoing burden.

Travel time, car parking, waiting rooms, and the clinical environment itself all have a cumulative effect. Some patients find hospital visits anxiety-provoking; others simply find the logistics difficult to manage alongside the fatigue that cancer treatment can bring. These are not trivial concerns.

What changed with the subcutaneous formulation

Subcutaneous pembrolizumab delivers the same drug in a format that can be administered under the skin - typically in the upper arm, thigh, or abdomen - without IV access or hospital infrastructure. The pivotal KEYNOTE-D18 trial established bioequivalence: patients receiving the subcutaneous formulation had equivalent drug exposure (measured by standard pharmacokinetic parameters) and no clinically meaningful difference in safety or efficacy outcomes.

The injection itself takes 3-5 minutes. This is the logistical foundation that makes home administration feasible. There is no drip, no IV line, and no need for the prepared infusion environment that the IV route requires.

How home administration works in practice

A qualified oncology nurse visits your home at each treatment cycle - typically every three or six weeks, depending on your prescribed schedule. Before the injection, baseline observations are taken. The injection is administered, usually into the upper arm. The nurse remains with you for a post-injection monitoring period, documents the visit, and communicates with your supervising oncologist.

The visit typically takes around 45-60 minutes in total, accounting for pre- and post-injection time. The actual injection is a small part of that. Between cycles, a remote check-in with the clinical team ensures that any emerging side effects are picked up and managed promptly.

Is the clinical outcome the same?

Based on the available evidence, yes. Bioequivalence data from KEYNOTE-D18 showed that the pharmacokinetic profiles of the subcutaneous and IV formulations are equivalent within accepted regulatory margins. The immune response - which is the mechanism driving anti-tumour activity - is the same regardless of route. The clinical difference is logistical, not therapeutic.

For the right patient, moving treatment home removes the hospital burden entirely while preserving the same clinical benefit. The question is whether you are a suitable candidate - which is what a thorough eligibility assessment is designed to determine.